https://www.selleckchem.com/pr....oducts/msdc-0160.htm
INTRODUCTION Akathisia continues to present a significant challenge in clinical practice. As a class, "atypical" or second-generation antipsychotics (SGAs) are the mainstay of treatment for schizophrenia and are commonly used to treat mood disorders. These medications have traditionally been distinguished from first-generation antipsychotics by their lowered risk of extrapyramidal side effects (EPS) such as dystonia, dyskinesia, akathisia, and pseudoparkinsonism. However, the occurrence of EPS, particularly akathisia, has been demonst
Like
Comment
Share
